



SARS-CoV-2 and Influenza A+B Antigen Combo Rapid Test (Nasopharyngeal Swab) Package Insert

REF ISIC-525 English

SARS-CoV-2 and Influenza A+B Antigen Combo Rapid Test is a rapid chromatographic immunoassay for the qualitative detection of SARS-CoV-2 Nucleocapsid protein, Influenza A and Influenza B virus antigens present in human nasopharynx. For professional *in vitro* diagnostic use only.

INTENDED USE

The SARS-CoV-2 and Influenza A+B Antigen Combo Rapid Test (Nasopharyngeal Swab) is a rapid chromatographic immunoassay for the qualitative detection of SARS-CoV-2 Nucleocapsid protein, Influenza A and Influenza B virus antigens in nasopharyngeal swab specimens from individuals with suspected SARS-CoV-2/Influenza infection in conjunction with clinical presentation and the results of other laboratory tests.

Results are for the detection of SARS-CoV-2 Nucleocapsid protein and Influenza A+B Antigens. An antigen is generally detectable in upper respiratory specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease.

Negative results do not preclude SARS-CoV-2/ Influenza A+B infection and should not be used as the sole basis for treatment or patient management decisions. Negative results should be treated as presumptive and confirmed with a molecular assay, if necessary for patient management. Negative results should be considered in the context of a patient's recent exposures, history and the presence of clinical signs and symptoms consistent with SARS-CoV-2/ Influenza A+B.

SUMMARY

The novel coronaviruses belong to the β genus. SARS-CoV-2 is an acute respiratory infectious disease. People are generally susceptible. Currently, the patients infected by the novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period is 1 to 14 days, mostly 3 to 7 days. The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases.

Influenza (commonly known as 'flu') is a highly contagious, acute viral infection of the respiratory tract. It is a communicable disease easily transmitted through the coughing and sneezing of aerosolized droplets containing live virus.¹ Influenza outbreaks occur each year during the fall and winter months. Type A viruses are typically more prevalent than type B viruses and are associated with most serious influenza epidemics, while type B infections are usually milder.

The gold standard of laboratory diagnosis is 14-day cell culture with one of a variety of cell lines that can support the growth of influenza virus.² Cell culture has limited clinical utility, as results are obtained too late in the clinical course for effective patient intervention. Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a newer method that is generally more sensitive than culture with improved detection rates over culture of 2-23%.³ However, RT-PCR is expensive, complex and must be performed in specialized laboratories.

PRINCIPLE

The SARS-CoV-2 and Influenza A+B Antigen Combo Rapid Test (Nasopharyngeal Swab) is a rapid chromatographic immunoassay for the qualitative detection of SARS-CoV-2 Nucleocapsid protein, Influenza A and Influenza B virus antigens in nasopharyngeal swab specimens from individuals. During testing, the specimen reacts with SARS-CoV-2 antibody-coated particles in the test. The mixture then migrates upward on the membrane by capillary action and reacts with the SARS-CoV-2 antibody in test line region. If the specimen contains SARS-CoV-2 Nucleocapsid protein, a colored line will appear in test line region as a result of this. If the specimen does not contain antigens to SARS-CoV-2, no colored line will appear in the test line region, indicating a negative result. To serve as a procedural control, a colored line will always appear in the control line region, indicating that the proper volume of specimen has been added and membrane wicking has occurred.

In this test, antibody specific to the Influenza A and Influenza B is separately coated on the test line regions of the test. During testing, the extracted specimen reacts with the antibody to Influenza A and/or Influenza B that are coated onto particles. The mixture migrates up the membrane to react with the antibody to Influenza A and/or Influenza B on the membrane and generate one or two colored lines in the test regions. The presence of this colored line in either or both of the test regions indicates a positive result. To serve as a procedural control, a colored line will always appear in the control region if the test has performed properly.

REAGENTS

The test contains anti-SARS-COV-2, anti-Influenza A and anti-Influenza B as the capture reagent, anti-SARS-COV-2, anti-Influenza A and anti-Influenza B as the detection reagent.

PRECAUTIONS

1. This package insert must be read completely before performing the test. Failure to follow directions in package insert may yield inaccurate test results.
2. For professional *in vitro* diagnostic use only. Do not use after expiration date.
3. Do not eat, drink or smoke in the area where the specimens or kits are handled.
4. Do not use test if pouch is damaged.
5. Handle all specimens as if they contain infectious agents. Observe established precautions against microbiological hazards throughout in the collection, handling, storage, and disposal of patient samples and used kit contents.
6. Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are assayed.
7. Viral Transport Media (VTM) may affect the test result, do not store specimens in viral transport media; extracted specimens for PCR tests cannot be used for the test.
8. Wash hands thoroughly after handling.
9. Please ensure that an appropriate amount of samples are used for testing. Too much or too little sample size may lead to deviation of results.
10. The used test should be discarded according to local regulations.
11. Humidity and temperature can adversely affect results.

STORAGE AND STABILITY

Store as packaged in the sealed pouch at room temperature or refrigerated (2-30 °C). The test is stable through the expiration date printed on the sealed pouch. The test must remain in the sealed pouch until use. **DO NOT FREEZE.** Do not use beyond the expiration date.

SPECIMEN COLLECTION, TRANSPORT AND STORAGE

Specimen Collection

1. Insert a sterile swab into the nostril of the patient, reaching the surface of the posterior nasopharynx.
2. Swab over the surface of the posterior nasopharynx 5-10 times.
3. Withdraw the sterile swab from the nasal cavity and avoid excess volume and highly-viscous nasopharyngeal discharge.



Caution: If the swab stick breaks during specimen collection, repeat specimen collection with a new swab.

Specimen transport and storage

Specimens should be tested as soon as possible after collection. If swabs are not been processed immediately, it is highly recommended the swab sample is placed into a dry, sterile, and tightly sealed plastic tube for storage. The swab specimen in dry and sterile condition is stable for up to 24 hours at 2-8 °C.

SPECIMEN PREPARATION

Only the extraction buffer and tubes provided in the kit is to be used for swab specimen preparation.

Please refer to the Procedure card for detailed information of Specimen Extraction.

1. Place the swab specimen in the Extraction tube with Extraction Buffer. Rotate the swab for approximately 10 seconds while pressing the head against the inside of the tube to release the antigen in the swab.
2. Remove the swab while squeezing the swab head against the inside of the Extraction tube as you remove it to expel as much liquid as possible from the swab. Discard the swab in accordance with your biohazard waste disposal protocol.

***NOTE:** The storage of the specimen after extraction is stable for 2 hours at room temperature or 24 hours at 2-8 °C.

MATERIALS

Materials provided

- Test cassettes
- Sterile swabs
- Package insert
- Extraction Buffer
- Extraction tubes and tips (Optional)
- Workstation
- Procedure card


Materials required but not provided

- Timer

DIRECTIONS FOR USE

Allow the test, extracted specimen and/or controls to equilibrate to room temperature (15-30 °C) prior to testing.

1. Remove the test cassette from the sealed foil pouch and use it within one hour. Best results will be obtained if the test is performed immediately after opening the foil pouch.
2. Invert the specimen extraction tube and add **3 drops of extracted specimen** (approx.75-100 μ l) to each of the specimen well (S) respectively and then start the timer.
3. Wait for the colored line(s) to appear. Read the result at **15 minutes**. Do not interpret the result after 20 minutes.



INTERPRETATION OF RESULTS

(Please refer to the illustration above)

POSITIVE SARS-CoV-2: Two colored lines appear in the left window. One colored line should be in the control region (C) and another colored line should be in the Test region (T). Positive result in the Test region indicates detection of SARS-CoV-2 antigens in the sample.

POSITIVE Influenza A: Two colored lines appear in the right window. One colored line should be in the control region (C) and another colored line should be in the Influenza A region (A). A positive result in the Influenza A region indicates that Influenza A antigen was detected in the sample.

POSITIVE Influenza B: Two colored lines appear in the right window. One colored line should be in the control region (C) and another colored line should be in the Influenza B region (B). A positive result in the Influenza B region indicates that Influenza B antigen was detected in the sample.

POSITIVE Influenza A and Influenza B: Three colored lines appear in the right window. One colored line should be in the control region (C) and two colored line should be in the Influenza A region (A) and Influenza B region (B). A positive result in the Influenza A region and Influenza B region indicates that Influenza A antigen and Influenza B antigen were detected in the sample.

***NOTE:** The intensity of the color in the test line region (T) will vary based on the amount of SARS-CoV-2 antigen, Flu A and/or B antigen present in the sample. So any shade of color in the test region (T/B/A) should be considered positive.

NEGATIVE: One colored line appears in the control region (C). No apparent colored line appears in the test line region (T/B/A).

INVALID: Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test with a new test Cassette. If the problem persists, discontinue using the test kit immediately and contact your local distributor.

QUALITY CONTROL

Internal Quality Control

Internal procedural controls are included in the test. A colored line appearing in the control region (C) is an internal positive procedural control. It confirms sufficient specimen volume and correct procedural technique.

External Quality Control

Controls are not included in this kit. However, in compliance with Good Laboratory Practice (GLP) positive/negative controls are recommended.⁴

LIMITATIONS

1. The test Procedure and the Interpretation of test Result must be followed closely when testing for the presence of SARS-CoV-2/Influenza A/Influenza B antigens in the human nasopharyngeal specimens from suspected individuals. For optimal test performance, proper sample collection is critical. Failure to follow the procedure may give inaccurate results.
2. The performance of the SARS-CoV-2 and Influenza A+B Antigen Combo Rapid Test (Nasopharyngeal swab) was evaluated using the procedures provided in this product

insert only. Modifications to these procedures may alter the performance of the test. Viral Transport Media (VTM) specimen and extracted specimens for PCR tests cannot be used for the test.

- The SARS-CoV-2 and Influenza A+B Antigen Combo Rapid Test (Nasopharyngeal swab) is for *in vitro* diagnostic use only. This test should be used for detection of SARS-CoV-2/Influenza A/Influenza B Antigens in human nasopharyngeal specimens as an aid in the diagnosis of patients with suspected SARS-CoV-2, Influenza A or Influenza B infection in conjunction with clinical presentation and the results of other laboratory tests. Neither the quantitative value nor the rate of increase in the concentration of SARS-CoV-2/Influenza A/Influenza B antigens can be determined by this qualitative test.
- The SARS-CoV-2 and Influenza A+B Antigen Combo Rapid Test (Nasopharyngeal Swab) will only indicate the presence of SARS-CoV-2/Influenza A/Influenza B Antigens in the specimen and should not be used as the sole criteria for the diagnosis of SARS-CoV-2/Influenza A/Influenza B infections.
- The results obtained with the test should be considered with other clinical findings from other laboratory tests and evaluations.
- If the test result is negative or non-reactive and clinical symptoms persist. It is recommended to re-sample the patient a few days later and test again or test with a molecular diagnostic device to rule out infection in these individuals.
- The test will show negative results under the following conditions:
 - The concentration of the novel coronavirus antigens, Influenza A or Influenza B virus in the sample is lower than the minimum detection limit of the test.
 - The optimal sampling time (peak virus concentration) after infection has not been verified, so collecting samples at different times for the same patient may avoid false negatives.
 - Incorrect specimen collection and storage.
- Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals.
- A negative result for Influenza A or Influenza B obtained from this kit should be confirmed by RT-PCR/culture.
- Positive results of SARS-CoV-2 may be due to infection with non-SARS-CoV-2 coronavirus strains or other interference factors. A positive result for influenza A and/or B does not preclude an underlying co-infection with another pathogen, therefore the possibility of an underlying bacterial infection should be considered.

[PERFORMANCE CHARACTERISTICS]

Limitation of detection

The detection level was 100 TCID₅₀/mL for SARS-CoV-2, 10 TCID₅₀/mL for Influenza A, 100 TCID₅₀/mL for Influenza B.

Sensitivity, Specificity and Accuracy

The SARS-CoV-2 and Influenza A+B Antigen Combo Rapid Test (Nasopharyngeal Swab) has been evaluated with specimens obtained from the patients. RT-PCR (Nasopharyngeal Swab) is used as the reference method for the SARS-CoV-2 and Influenza A+B Antigen Combo Rapid Test (Nasopharyngeal Swab). Specimens were considered positive if RT-PCR (Nasopharyngeal Swab) indicated a positive result. Specimens were considered negative if RT-PCR (Nasopharyngeal Swab) indicated a negative result.

SARS-CoV-2 Test:

SARS-CoV-2 and Influenza A+B Antigen Combo Rapid Test	RT-PCR(Nasopharyngeal Swab)		Total
	Positive	Negative	
SARS-CoV-2	99	2	101
Influenza A+B Antigen	7	316	323
Total	106	318	424
Relative Sensitivity	93.4% (95%CI*: 86.9%~97.3%)		
Relative Specificity	99.4% (95%CI*: 97.8%~99.9%)		
Accuracy	97.9% (95%CI*: 96.0%~99.0%)		

Influenza A+B Test :

SARS-CoV-2 and Influenza A+B Antigen Combo Rapid Test	Type A			Type B		
	RT-PCR		Total	RT-PCR		Total
	Positive	Negative		Positive	Negative	
Flu A+B	36	4	40	40	5	45
	2	223	225	3	217	220
Total	38	227	265	43	222	265
Relative Sensitivity	94.7% (95%CI*: 81.8%~99.5%)			93.0% (95%CI*: 80.7%~98.3%)		
Relative Specificity	98.2% (95%CI*: 95.4%~99.5%)			97.7% (95%CI*: 94.5%~99.2%)		
Accuracy	97.7% (95%CI*: 95%~99.1%)			97.0% (95%CI*: 94.1%~98.6%)		

***Confidence Intervals**

Specificity Testing with Various Viral Strains

The SARS-CoV-2 and Influenza A+B Antigen Combo Rapid Test was tested with the following viral strains. No discernible line at either of the test-line regions was observed at these concentrations listed:

SARS-CoV-2 Test:

Description	Test Level
Adenovirus type 3	3.16 x 10 ⁴ TCID ₅₀ /mL
Adenovirus type 7	1.58 x 10 ⁵ TCID ₅₀ /mL
Human coronavirus OC43	1 x 10 ⁶ TCID ₅₀ /mL
Human coronavirus 229E	5 x 10 ⁵ TCID ₅₀ /mL
Human coronavirus NL63	1 x 10 ⁶ TCID ₅₀ /mL
Human coronavirus HKU1	1 x 10 ⁶ TCID ₅₀ /mL
MERS COV Florida	1.17 x 10 ⁴ TCID ₅₀ /mL
Influenza A H1N1	3.16 x 10 ⁵ TCID ₅₀ /mL
Influenza A H3N2	1 x 10 ⁵ TCID ₅₀ /mL
Influenza B	3.16 x 10 ⁶ TCID ₅₀ /mL
Human Rhinovirus 2	2.81 x 10 ⁴ TCID ₅₀ /mL
Human Rhinovirus 14	1.58 x 10 ⁶ TCID ₅₀ /mL
Human Rhinovirus 16	8.89 x 10 ⁶ TCID ₅₀ /mL
Measles	1.58 x 10 ⁴ TCID ₅₀ /mL
Mumps	1.58 x 10 ⁴ TCID ₅₀ /mL
Parainfluenza virus 2	1.58 x 10 ⁷ TCID ₅₀ /mL
Parainfluenza virus 3	1.58 x 10 ⁸ TCID ₅₀ /mL
Respiratory syncytial virus	8.89 x 10 ⁴ TCID ₅₀ /mL

Influenza A+B Test:

Description	Test Level
Adenovirus type 3	3.16 x 10 ⁴ TCID ₅₀ /mL
Adenovirus type 7	1.58 x 10 ⁵ TCID ₅₀ /mL
Human coronavirus OC43	1 x 10 ⁶ TCID ₅₀ /mL
Human coronavirus 229E	5 x 10 ⁵ TCID ₅₀ /mL
Human coronavirus NL63	1 x 10 ⁶ TCID ₅₀ /mL
Human coronavirus HKU1	1 x 10 ⁶ TCID ₅₀ /mL
MERS COV Florida	1.17 x 10 ⁴ TCID ₅₀ /mL
Human Rhinovirus 2	2.81 x 10 ⁴ TCID ₅₀ /mL
Human Rhinovirus 14	1.58 x 10 ⁶ TCID ₅₀ /mL
Human Rhinovirus 16	8.89 x 10 ⁶ TCID ₅₀ /mL
Measles	1.58 x 10 ⁴ TCID ₅₀ /mL
Mumps	1.58 x 10 ⁴ TCID ₅₀ /mL
Parainfluenza virus 2	1.58 x 10 ⁷ TCID ₅₀ /mL
Parainfluenza virus 3	1.58 x 10 ⁸ TCID ₅₀ /mL
Respiratory syncytial virus	8.89 x 10 ⁴ TCID ₅₀ /mL

TCID₅₀ = Tissue Culture Infectious Dose is the dilution of virus that under the conditions of the assay can be expected to infect 50% of the culture vessels inoculated.

Precision

Intra-Assay & Inter-Assay

Within-run and Between-run precision has been determined by using seven specimens of SARS-CoV-2 and Influenza A/B standard control. Three different lots of SARS-CoV-2 and Influenza A+B Antigen Combo Rapid Test (Nasopharyngeal Swab) have been tested using negative specimen, SARS-COV-2 Antigen weak and Strong positive specimen, Influenza A weak and strong positive specimen, Influenza B Weak and strong positive specimen. Ten replicates of each level were tested each day for 3 consecutive days. The specimens were correctly identified >99% of the time.

Cross-reactivity

The following organisms were tested at 1.0x10⁸ org/mL and all found to be negative when tested with the SARS-CoV-2 and Influenza A+B Antigen Combo Rapid Test (Nasopharyngeal Swab):

<i>Arcanobacterium</i>	<i>Pseudomonas aeruginosa</i>
<i>Candida albicans</i>	<i>Staphylococcus aureus subsp. aureus</i>
<i>Corynebacterium</i>	<i>Staphylococcus epidermidis</i>
<i>Escherichia coli</i>	<i>Streptococcus pneumoniae</i>
<i>Moraxella catarrhalis</i>	<i>Streptococcus pyogenes</i>
<i>Neisseria lactamica</i>	<i>Streptococcus salivarius</i>
<i>Neisseria subflava</i>	<i>Streptococcus sp group F</i>

Interfering Substances

Test results will not be interfered by following substances at certain concentrations:

Substance	Concentration	Substance	Concentration
Whole Blood	20 µl/mL	Oxymetazoline	0.6 mg/mL
Mucin	50 µg/mL	Phenylephrine	12 mg/mL
Budesonide Nasal Spray	200 µl/mL	Rebetol	4.5 µg/mL
Dexamethasone	0.8 mg/mL	Relenza	282 ng/mL
Flunisolide	6.8 ng/mL	Tamiflu	1.1 µg/mL
Mupirocin	12 mg/mL	Tobramycin	2.43 mg/mL

[BIBLIOGRAPHY]

- Williams, KM, Jackson MA, Hamilton M. (2002) Rapid Diagnostic Testing for URIs in Children; Impact on Physician Decision Making and Cost. *Infect. Med.* 19(3): 109-111.
- Betts, R.F. 1995. Influenza virus, p. 1546-1567. In G.L. Mandell, R.G. Douglas, Jr. and J.E. Bennett (ed.), *Principle and practice of infectious diseases*, 4th ed. Churchill Livingstone, Inc., New York, N.Y.
- WHO recommendations on the use of rapid testing for influenza diagnosis, World Health Organisation, July 2005.
- Westgard JO, Barry PL, Hunt MR, Groth T. A multi-rule Shewhart for quality control in clinical chemistry, *Clinical Chemistry* 1981;27:493-501.

Index of Symbols

	For <i>in vitro</i> diagnostic use only		Tests per kit		Authorized Representative
	Store between 2-30°C		Use by		Do not reuse
	Do not use if package is damaged		Lot Number		Catalog #
	Manufacturer		Consult Instructions For Use		

Hangzhou AllTest Biotech Co., Ltd.
 #550, Yinhai Street
 Hangzhou Economic & Technological Development Area
 Hangzhou, 310018 P.R. China
 Web: www.alltests.com.cn Email: info@alltests.com.cn

EC REP
 MedNet EC-REP GmbH
 Borkstrasse 10,
 48163 Muenster,
 Germany

Innova Medical Group bv
 Suite 310
 Grote Bick rsstraat 74-78 1013
 KS, Ams erdam
 The etherlands
 Tel. : +31 (0)202 250 170
 Emajl : Info@inn vameggroup.eu

Service Clients / Customer Service
 Tel. : +33 (0)1 87 20 01 25
 Email : commercial@innovamedgroup.com

Statement: Information about manufacturer of sterile swab is placed on the packaging.

Number: 146792900
 Effective Date: 2022-06-06